Valrubicin (N-trifluoroacetyladriamycin-14-valerate), a semisynthetic analog of the anthra-cycline doxorubicin, is a cytotoxic agent.
VALSTAR is indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.
Media Articles Related to Valstar (Valrubicin)
Source: MedicineNet Biological Therapy Specialty [2013.11.26]
Title: Bladder Cancer
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 11/26/2013 12:00:00 AM
Study Finds Bladder Cancer Recurrence And Mortality Could Improve With Better Treatment Compliance
Source: Compliance News From Medical News Today [2013.06.05]
Researchers at UCLA's Jonsson Comprehensive Cancer Center led by Dr. Karim Chamie, assistant professor-in-residence in the department of urology, have found that the burden of bladder cancer on the population is very high, and that more intense surveillance and treatment in the first two years after diagnosis could reduce the number of patients whose cancer returns after treatment and lower the...
Study Claims Marijuana Tied to Lower Bladder Cancer Risk
Source: MedicineNet Bladder Cancer Specialty [2013.05.13]
Title: Study Claims Marijuana Tied to Lower Bladder Cancer Risk
Category: Health News
Created: 5/10/2013 6:35:00 PM
Last Editorial Review: 5/13/2013 12:00:00 AM
Heavy Smoking May Raise Odds for Lethal Bladder Cancer
Source: MedicineNet Bladder Cancer Specialty [2013.01.14]
Title: Heavy Smoking May Raise Odds for Lethal Bladder Cancer
Category: Health News
Created: 1/14/2013 12:35:00 PM
Last Editorial Review: 1/14/2013 12:00:00 AM
Another Study Links Diabetes Drug Actos to Bladder Cancer
Source: MedicineNet pioglitazone Specialty [2012.07.05]
Title: Another Study Links Diabetes Drug Actos to Bladder Cancer
Category: Health News
Created: 7/3/2012 2:05:00 PM
Last Editorial Review: 7/5/2012 12:00:00 AM
Published Studies Related to Valstar (Valrubicin)
Factors affecting valrubicin response in patients with bacillus Calmette-Guerin-refractory bladder carcinoma in situ. [2011.05]
OBJECTIVE: Patients with bacillus Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the bladder are candidates for intravesical (IVe) valrubicin. This post-hoc analysis of data from the pivotal phase 3, prospective, open-label study of valrubicin evaluated the effects of patient characteristics and past treatments on the response to valrubicin... CONCLUSIONS: In these patients with BCG-refractory CIS, complete responders to valrubicin did not differ significantly from partial or nonresponders in the number of prior courses or instillations. The results suggest that therapy with valrubicin may be considered in appropriate candidates who have not responded to prior therapies. Cystectomy should be reconsidered when valrubicin treatment fails.
Topical application of valrubicin has a beneficial effect on developing skin tumors. [2010.08]
Valrubicin is a second generation anthracycline characterized by an excellent safety profile presenting no skin toxicity or necrosis upon contact...
Valrubicin in a topical formulation treats psoriasis in a xenograft transplantation model. [2010.02]
Valrubicin is a cytostatic drug currently approved by the American Federal Drug Administration as a trademarked Valstar sterile solution for the treatment of bladder cancer. Valrubicin has shown an excellent therapeutic potential with minimal toxicity.
Clinical Trials Related to Valstar (Valrubicin)
Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma [Recruiting]
The purpose of this study is to learn more about how well the drug valrubicin (VALSTARŪ)
works to help treat the patient's cancer when administered through a nephrostomy tube
inserted through their back into their kidney. The study is also being done to determine how
safe and easy it is to tolerate valrubicin at specific dose levels, as well as the way in
which the drug is eliminated from the human body (Pharmacokinetics or PK).
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer [Not yet recruiting]
The use of a designed viral vector that can destroy cancer cells while leaving normal cells
largely unharmed. The virus also stimulates an immunological response by producing a special
factor (GM-CSF) to attract and promote the development of dendritic and T effector cells. It
forms the hypothesis that this regimen may be used for people who have failed current forms
of treatment and are recommended for cystectomy. It is with hope that this novel therapy
will be able to delay or potentially avoid cystectomy for this patient population. Bladder
instillation of this agent causes little long lasting side effects and may drastically
improve the stimulation of the immune system for local cancer cell death as well as
destroying those tumor cells that may have travelled to regional lymph nodes or distant